echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > First-line treatment of kidney cancer: Mercadon / Weishi "Immunity and Targeting" combination Keytruda and Lenvima Phase 3 Clinical: Efficacy beats Schoinidini!

    First-line treatment of kidney cancer: Mercadon / Weishi "Immunity and Targeting" combination Keytruda and Lenvima Phase 3 Clinical: Efficacy beats Schoinidini!

    • Last Update: 2021-02-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Lenvima is an oral polymethyme tyrosine kinase (RTK) inhibitor with novel binding patterns that inhibit other angiogenesphage and cancer-causing signaling pathogenesies associated with thyroid-derived growth factors (PDGs) in addition to inhibition of other angiogenesphageal, tumor progression, and tumor immunomodulation. In addition to PDGFR alpha, KIT and RET, the F) and fibroblast growth factor (FGFR1, VEGFR2, VEGFR3) and fibroblast growth factor (FGFF) are selectively inhibited by kinase activity of vascular enditer growth factor (VEGFR3, FGFR3, FGFR4).
    Keytruda is an anti-PD-1 tumor immunotherapy that helps detect and fight tumor cells by improving the body's immune system.
    Keytruda is an anthogeneic monoclonal antibody that blocks the interaction between PD-1 and its mediators PD-L1 and PD-L2, activating T lymphocytes that may affect tumor cells and healthy cells.
    Currently, Mercadon and Isashi are developing 14 different types of tumors (endometrial, hepatocellular, melanoma, non-small cell lung, renal cell carcinoma, The Keytruda-Lenvima combination continued to be studied in 20 clinical trials of head and neck squamous cell carcinoma, urethra cancer, bile tube cancer, colorectal cancer, stomach cancer, glioblastoma, ovarian cancer, pancreatic cancer, and triple-negative breast cancer.
    two trials of the LEAP project, published in September 2020, showed that the Keytruda-Lenvima combination showed efficacy in all seven types of tumors.
    () Original origin: KEYTRUDA® Plus LENVIMA® (lenvatinib) Progress Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versussusinib as First-Line Treatment for Patients With Advanced Renal Cell > Carcin

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.